<DOC>
	<DOCNO>NCT01593735</DOCNO>
	<brief_summary>This multiple dose study safety efficacy MK-2748 do 2 Parts . Part I enroll genotype 1 ( GT1 ) hepatitis C virus ( HCV ) -infected participant Part II enroll genotype 3 ( GT3 ) HCV-infected participant . Both Parts may run concurrently may stagger .</brief_summary>
	<brief_title>A Multiple Dose Study Evaluate Safety Efficacy MK-2748 Hepatitis C-Infected Participants ( MK-2748-002 AM1 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis chronic HCV infection ( GT1 GT3 ) least 6 month detectable HCVRNA peripheral blood Body mass index ( BMI ) 18 37 kg/m^2 No clinically significant abnormality electrocardiogram ( ECG ) Stable health Willing use appropriate contraception throughout study 90 day last dose study drug Exclusion criterion : Participant pregnant breastfeeding , expect conceive father child within project duration study History stroke , chronic seizure , major neurological disorder History clinically significant endocrine , gastrointestinal ( except HCV infection ) , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases History neoplastic disease ( exception adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix , malignancy successfully treat ≥10 year prior unlikely recur Positive Hepatitis B surface antigen Documented human immunodeficiency virus ( HIV ) infection Consumption excessive amount alcohol , define great 2 glass alcoholic beverage ( 1 glass approximately equivalent : beer [ 284 mL/10 ounce ] , wine [ 125 mL/4 ounce ] , distilled spirit [ 25 mL/1 ounce ] ) per day Consumption excessive amount , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day Major surgery , donate lose 1 unit blood ( approximately 500 mL ) within 4 week prior study enrollment History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Current regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 2 month prior enrollment Evidence history chronic hepatitis cause HCV include limited nonHCV viral hepatitis , nonalcoholic steatohepatitis ( NASH ) , drug induce hepatitis , autoimmune hepatitis Previous treatment HCV NS3/4A protease inhibitor Previous exposure interferonalpha and/or ribavirin within 3 month prior study enrollment Clinical laboratory evidence advance decompensated liver disease ; evidence bridge fibrosis high grade fibrosis ( Metavir score ≥3 ) Participation another investigational study within 4 week prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>